Key Takeaways VKTX finished enrollment of about 4,650 adults in the phase III VANQUISH-1 study of obesity drug VK2735.The study tests three weekly SC doses versus placebo, tracking body-weight change after 78 weeks.Rapid recruitment follows earlier full enrollment of the phase II VENTURE-Oral Dosing study this year.Viking Therapeutics (VKTX) announced that it has completed enrolling study participants in the phase III VANQUISH-1 study, which is evaluating the safety and efficacy of the subcutaneous (SC) for ...

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

MARKET TRENDS: Stay Profitable And Protected With This Routine Shares of Ligand Pharmaceuticals (LGND) are absolutely flying, up almost 88% this year, as investors line up behind the company's unique royalty-based business model. Ligand Pharma is a biotech company that doesn't make biologic medicines. Instead, it makes deals. The company has a portfolio of more than 90 partnered commercial and development-stage drugs, including treatments for cancer, kidney disease, diabetes,… Related news Drug Giant Merck ...

Key Takeaways Merck's DOR/ISL matched Biktarvy in a phase III HIV study, meeting efficacy and safety goals.DOR/ISL's positive data support upcoming approval filings for treatment-naive HIV patients.The EU approved Keytruda SC, offering quicker dosing versus the IV version across all solid tumor uses.Merck (MRK) announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg ...

Summary of Merck & Co (NYSE:MRK) 2025 Conference Call Company Overview - **Company**: Merck & Co (also known as MSD in certain regions) [2][4] - **Focus**: The company is actively involved in the development of innovative therapies, particularly in the fields of infectious diseases, oncology, and chronic conditions. Key Industry Insights Acquisition and Product Development - **Cidara Acquisition**: Merck's acquisition of Cidara is aimed at enhancing its vaccine-adjacent business, particularly in the flu market with a long-acting antiviral [3][5] - **Long-Acting Antiviral**: The new antiviral shows 76% efficacy against influenza, with a potential market of 110 million people in the U.S., including 85 million with underlying health conditions [7][8] - **Economic Impact**: The previous flu season saw 1.6 million hospitalizations in the U.S., highlighting the economic and health benefits of the new antiviral [8][9] Regulatory and Market Strategy - **FDA Engagement**: The FDA has shown interest in expanding the patient population for the phase three program of the antiviral, indicating alignment with public health strategies [11][13] - **Market Adoption**: The company is optimistic about the uptake of the antiviral, emphasizing its strain-agnostic nature and potential for broad public health impact [15][16] Oncology Developments - **Winrevair for PAH**: The launch of Winrevair has been transformative for patients with pulmonary arterial hypertension (PAH), with ongoing patient initiation rates of about 500 per month in the U.S. [21][23] - **Sactuzumab Govitecan**: This drug is positioned as a versatile treatment for various cancers, with 15 registration studies ongoing, aiming to provide effective options for community oncologists [48][49] HIV Treatment Innovations - **Islatravir/Derivery**: A new daily two-drug regimen that is non-inferior to Biktarvy, with a PDUFA date set for April next year. This regimen aims to address the need for alternatives to integrase inhibitors [58][66] - **Monthly PrEP Option**: A long-acting oral PrEP option is in development, which could appeal to patients preferring convenience over injections, representing a multi-billion dollar opportunity in the HIV market [63][65] Additional Insights - **Market Needs**: There is a significant unmet medical need in various patient populations, particularly in oncology and chronic diseases, which Merck aims to address through innovative therapies [27][29] - **Patient-Centric Approach**: The company emphasizes the importance of patient education and government support in driving product uptake, especially in the context of vaccine hesitancy [10][11] Conclusion Merck & Co is strategically positioning itself in the pharmaceutical market through acquisitions, innovative product development, and a focus on addressing unmet medical needs across various therapeutic areas. The company's proactive engagement with regulatory bodies and emphasis on patient-centric solutions are expected to drive future growth and market adoption.

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve). • MRK shares are experiencing downward pressure. Check out the latest moves here.The success criterion for the primary efficacy hypothesis, as measured by the percentage of participants with HIV-1 RNA levels <5 ...

Key Takeaways MRK's Winrevair met the primary endpoint in the CADENCE study in adults with CpcPH tied to HFpEF.Winrevair cut pulmonary vascular resistance at 24 weeks versus placebo, with safety in line with known data.MRK plans to present results at a future conference and advance Winrevair to phase III in this populationMerck (MRK) announced that the phase II CADENCE study, which evaluated its newly launched pulmonary arterial hypertension (“PAH”) drug Winrevair, for treating adults with combined post and ...

NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2025 Conference November 19, 2025 07:00 AM ET Company ParticipantsJohn Kastelein - CSOIan Somaiya - CFOConference Call ParticipantsDennis Ding - Biotech AnalystDennis DingHi, good afternoon. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having NewAmsterdam Pharma here. We have the CSO, John Kastelein, and CFO, Ian Somaiya, here with us. Welcome.Ian SomaiyaThank you ...

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of ...

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. ...